Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
The model's full reasoning — Q4 2022 call → NOWe need to determine if management grounds its case in observed customer or counterparty behavior from the recent period, with concrete actions revealing genuine preference, and treats that as core proof with more ahead. Scan the transcript for mentions of counterparty behavior. Management discusses partnerships, clinical trials, regulatory interactions, etc. They mention Takeda submitting Phase 3 protocol, waiting for FDA feedback. They mention Amgen's olpasiran data. They mention Royalty Pharma deal. They mention their own pipeline progress. But do they point to specific observed behavior of customers or partners that shows commitment? For example, partners paying milestones, initiating studies, etc. They mention "we expect to receive milestone payments from each over the next 12 months" - that's future expectation, not observed current behavior. They mention Takeda submitted a Phase 3 protocol - that's a concrete action by a partner, but is it described as recent observed behavior that reveals commitment? Yes, Takeda is actively moving forward. But is that the core proof of growth? Management's case seems to be about their own pipeline progress, data, and plans. They talk about "clarity" and "progress" but not about customers or partners doing things that show preference beyond contractual obligations. The Royalty Pharma deal is a financial transaction, not a customer behavior. The clinical trial enrollment? They mention PALISADE is 50% enrolled - that's a trial, not a customer behavior. They mention "we are approaching full enrollment" for SAD cohorts - that's internal progress. The question asks: does management ground its case in observed customer or counterparty behavior? They mention Takeda's actions, but that's a partner, not a customer. The company's business model includes partnerships. But the question is about "customers, buyers, users, or partners" - so partners count. Takeda submitting a Phase 3 protocol is a concrete action. But is it described as recent and showing commitment? Yes, they say "Takeda submitted a Phase 3 protocol to the U.S. FDA at the end of last quarter" - that's a specific action. And they are waiting for feedback. That shows Takeda is moving forward. But is that the core proof of growth? Management's case is more about their own pipeline and data.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
ULCC · Q1 2023 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management points to concrete recent-period behavior: over half of GoWild Pass sales so far are from customers with no prior travel history with Frontier, plus overwhelmingly positive feedback and customers taking the product to social media. They treat this observed adoption pattern as central proof that the offering is working and will keep growing, with the 90%+ repeat rate and $85–$100 per-passenger contribution goals still ahead of current results. They also cite the shift in consumer demand patterns (leisure travel increasingly favoring peak days, expanding RASM premium from 19% to over 25%) as direct evidence of customer preference that is reshaping capacity and margins. These elements are presented as the behavioral foundation for continued growth rather than merely company results or plans.
PCRX · Q4 2017 → YESThe question is: Does management ground their case for why the business is working and will keep growing in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in concrete, observed counterparty behavior—specifically J&J’s sales team activating accounts and training customers on EXPAREL technique, with the number of activated accounts continuing to grow, plus J&J committing to a six-fold increase in PEAK programs (already exceeding 2018 plans). They also cite commercial payers paying for EXPAREL under C9290 as a medical benefit and hospitals gaining access through surgeon relationships, treating these patterns as central proof that the offering is being chosen and valued, with the business still early and expanding ahead.
PPC · Q1 2024 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in observed counterparty behavior by citing concrete patterns such as key customers increasing marketplace presence, deli and QSRs showing steady performance, brands growing faster than category averages in Europe, key customer partnerships driving growth in Mexico, and key customers outpacing industry growth in domestic chicken volumes and value-added products — all presented as recent, specific actions by buyers and partners that demonstrate genuine preference and commitment, with the business still building further through continued diversification and new opportunities.